Case Study: Moderna Therapeutics achieves faster, lower-cost mRNA drug development with Amazon Web Services

Moderna Therapeutics Delivers mRNA Drugs Faster, at Lower Cost Using AWS

Moderna Therapeutics, a Cambridge, MA–based biotech founded to develop mRNA medicines, faced the industry’s typical hurdles: decade‑long, billion‑dollar drug timelines, complex GxP/FDA compliance, siloed data, and the need for scalable, high‑performance compute to support automation and enterprise‑wide integration for research, development, and manufacturing.

By migrating core systems to AWS (including EC2 with Spot and Auto Scaling, S3, RDS, SQS/SNS, and Redshift) Moderna built its Drug Design Studio and a GxP‑validated cloud ecosystem that integrates lab, manufacturing, and ERP systems. The result: dramatically faster preclinical development (a Zika vaccine reached clinical trials in one year), millions saved versus on‑premises infrastructure, consolidated data and compliance workflows, and an AWS environment managed by a single staff member that supports a growing pipeline of mRNA drugs.

Moderna Therapeutics

Marcello Damiani

Chief Digital Officer